Agile Therapeutics, a specialty pharmaceutical company focused on women's healthcare products, has appointed Al Altomari as chairman of its board of directors. Altomari currently serves as CEO of Barrier Therapeutics. Prior to Barrier, Altomari held several executive roles at Johnson & Johnson, and worked for Ortho-McNeil Pharmaceutical's women's health care franchise.
Introgen Therapeutics, a developer of molecular therapies for cancer, has appointed James Rothman, PhD, to the company's board of directors. Rothman previously served as vice chairman of the Sloan-Kettering Research Institute of Memorial Sloan-Kettering cancer Center.